Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia
Condition: CD22 Positive; Recurrent Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia
MeSH terms: Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphoid
Intervention: Inotuzumab Ozogamicin
Intervention description: Given IV
Intervention MeSH terms: Inotuzumab Ozogamicin
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 4.0
Sex: All
Minimum age: 12 Years
Healthy volunteers: No

Summary:

      This phase II trial studies how well inotuzumab ozogamicin works in treating patients with
      CD22 positive acute lymphoblastic leukemia that has come back or does not respond to
      treatment. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a
      toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a
      targeted way and delivers ozogamicin to kill them.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Patients at least 12 years of age

          -  Patients with a diagnosis of CD22-positive acute lymphoblastic leukemia (ALL) based on
             local immunophenotyping and histopathology who have:

               -  Refractory disease, defined as disease progression or no response while receiving
                  their most recent prior anti-cancer therapy,

               -  Relapsed disease, defined as response to their most recent prior anti-cancer
                  therapy with subsequent relapse

          -  Performance status of 0 to 3

          -  Serum creatinine =< 2 x upper limit of normal (ULN) or estimated creatinine clearance
             >= 15 mL/min as calculated using the method standard for the institution

          -  Total serum bilirubin =< 1.5 x ULN unless the patient has documented Gilbert syndrome.
             If organ function abnormalities are considered due to tumor, total serum bilirubin
             must be =< 2 x ULN

          -  Aspartate and alanine aminotransferase (AST or ALT) =< 2.5 x ULN

          -  No active or co-existing malignancy requiring chemotherapy or radiation within 6
             months

          -  Female subjects of childbearing potential should be willing to use effective methods
             birth control or be surgically sterile, or abstain from heterosexual activity for the
             course of the study. Subjects of childbearing potential are those who have not been
             surgically sterilized or have not been free from menses for > 1 year. Effective
             methods of birth control include birth control pills or injections, intrauterine
             devices (IUDs), or double-barrier methods (for example, a condom in combination with
             spermicide)

          -  Male subjects should agree to use an effective method of contraception starting with
             the first dose of study therapy through the duration of treatment

        Exclusion Criteria:

          -  Pregnant or nursing women

          -  Known to be human immunodeficiency virus (HIV)+

          -  Philadelphia chromosome (Ph)+ ALL

          -  Active and uncontrolled disease/infection as judged by the treating physician

          -  Unable or unwilling to sign the consent form

          -  Prior allogeneic stem cell transplantation (ASCT) or other anti-CD22 immunotherapy
             within =< 4 months before first dose of study treatment

          -  Active central nervous system (CNS) or extramedullary disease unless approved by the
             principal investigator (PI)

          -  Monoclonal antibodies therapy within 2 weeks before study entry

          -  Radiotherapy and cancer chemotherapy (except for intrathecal chemotherapy,
             hydroxyurea, and cytarabine. Cytarabine and hydroxyurea are allowed to be used
             emergently in case of leukocytosis) or any investigational drug within 2 weeks before
             study entry

          -  Evidence or history of veno-occlusive disease (VOD) or sinusoidal obstruction syndrome
             (SOS)